Valuable data can successfully be collected with the noninvasive wearable, which is worn on the sternum, report investigators ...
Zacks Small Cap Research on MSN9d
WINT: Patient Enrollment in SEISMiC C Trial Starts, Patent Position ExpandsWINT Enrolling SCAI Stage C participants in SEISMiC C trial, preparing for Phase 3 readiness Pennsylvania-based Windtree ...
This medication is a sympathomimetic compound used in the treatment of heart failure and cardiogenic shock. It stimulates the heart muscle. •Correct the decreased blood volume prior to treatment.
When the heart has difficulty pumping blood adequately, it is known as cardiogenic shock ... The most common cause of obstructive shock is a massive pulmonary embolism (blood clot that has traveled to ...
Department of Critical Care Medicine and Division of Cardiology, Department of Medicine, University of Alberta, Edmonton, Canada (S.v.D., J.M.S.). Department of Critical Care Medicine and Division of ...
Background: In the Danish–German Cardiogenic Shock (DanGer Shock) trial, use of a microaxial flow pump (mAFP) in patients with ST-segment elevation myocardial infarction (STEMI)-related CS led to ...
Macular edema is swelling or fluid retention in a specialized part of the retina called the macula. The macula is located in the back of the eye and provides us with clear, central vision. It is the ...
The istaroxime patent is entitled, “ISTAROXIME-CONTAINING INTRAVENOUS FORMULATION FOR THE TREATMENT OF PRE-CARDIOGEN1C SHOCK AND CARDIOGENIC SHOCK”, is No. PCT/US2023/018998 and was assigned ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback